Patent details

92684 Product Name: Fidaxomicine ou son sel pharmaceutiquement acceptable

Basic Information

Publication number:
92684
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP037847662
Legal Status:
Active
Application number:
92684
First applicant's nationality:
Procedural language:
French

Paediatric Extension

SPC Extension Filing Date:
10/08/2020
SPC Extension Agent Name:
KIRKPATRICK
SPC Extension Status:
Granted
SPC Extension Grant Date:
29/12/2021
SPC Extension Rejection Date:

Marketing Authorization

Marketing Authorization Number:
EU/1/11/733/001-002-004 - Dificlir
Marketing Authorization Type:
Marketing Authorization Date:
07/12/2011
Marketing Authorization Status:
Accepted
Marketing Authorization Country:

Dates

Filing date:
26/03/2015
First Marketing Authorization date:
07/12/2011
Grant date:
02/11/2015
Activation date:
15/07/2023
Publication date:
02/11/2015
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
07/12/2026
SPC Extension Expiration:
07/06/2027
Rejection date:
Withdrawal date:

Owner

From:
16/09/2022
 
 

Name:
MERCK SHARP & DOHME LLC
Address:
126 East Lincoln Avenue, 07065, Rahway, New Jersey , United States (US)

History of Owners

From:
29/09/2015
To:
16/09/2022

Name:
MERCK SHARP & DOHME CORP.
Address:
EAST LINCOLN AVENUE 126, RAHWAY, NJ 07065, United States (US)

From:
26/03/2015
To:
28/09/2015

Name:
Optimer Pharmaceuticals Inc.
Address:
65 Hayden Avenue, Lexington, MA 02421, United States (US)

Agent

Name:
KIRKPATRICK
From:
26/03/2015
Address:
AVENUE WOLFERS 32, 1310, LA HULPE, Belgium (BE)
To:

Inventor

1

Name:
DU Chi-Jen, Frank
Address:
Taiwan (TW)

2

Name:
SHUE Youe-Kong
Address:
United States (US)

3

Name:
CHIOU Ming-His
Address:
Taiwan (TW)

4

Name:
WU Mei-Chiao
Address:
Taiwan (TW)

5

Name:
DUFFIELD Jonathan, James
Address:
United States (US)

6

Name:
OKUMU Franklin, W.
Address:
United States (US)

7

Name:
CHEN Yuan-Ting
Address:
Taiwan (TW)

Publication

Bulletin

1

Bulletin Heading:
SPCX1
Bulletin edition number:
2020/10
Publication date:
04/09/2020
Description:
Section G : Applications for extensions for pediatric use – I1E publication

2

Bulletin Heading:
SPCX2
Bulletin edition number:
2022/01
Publication date:
03/01/2022
Description:
Section H : Granted extensions for pediatric use of supplementary protection certificates – I2E publication

3

Bulletin Heading:
CO
Bulletin edition number:
2022/12
Publication date:
08/11/2022
Description:
Section M : Transfers of property (Art. 53 of the law), change of name and/or address

4

Bulletin Heading:
SPC3
Bulletin edition number:
2025/04
Publication date:
04/03/2025
Description:
Section E : Supplementary Protection certificates entered into force – IA publication

Deed

Change of owner(s)

Change Kind/ Decision Type:
Change of ownership
Deed Number:
RC20220000377A
Date Registered:
16/09/2022
Licence Effective Date:
Licence Expiration Date:
Scope of Licence:
Deed Filer:
MARKS & CLERK LLP
Journal Edition Number:
Text:
Country Code:
Updated Licence Number:
Terminated Licence Number:

Added Owner(s)

Name:
MERCK SHARP & DOHME LLC
Address:
126 East Lincoln Avenue, 07065, Rahway, New Jersey , United States (US)

Removed Pledgee

Name:
Address:

Annual Fees

Annual Fee Due Date:
31/07/2026
Annual Fee Number:
24
Annual Fee Amount:
440 Euro
Expected Payer:
Last Annual Fee Payment Date:
17/06/2025
Last Annual Fee Paid Number:
23
Last Annual Fee Paid Amount:
430 Euro
Payer:
MASTER DATA CENTER INC (ex Clarivate Analytics)
Filing date Document type Number of pages
10/08/2020 General Document 3
10/08/2020 Application Form 3
03/01/2022 Outgoing Correspondence 1
10/08/2020 General Document 25
10/08/2020 FNET_DC_FRONTPAGE 1
10/08/2020 General Document 3
29/12/2021 Certificate 1
10/08/2020 Publication 1
10/08/2020 General Document 4
29/12/2021 Publication 1
10/08/2020 General Document 49
10/08/2020 General Document 1
10/08/2020 Outgoing Correspondence 1
10/08/2020 Incoming Correspondence (Post) 2
10/08/2020 General Document 4
16/09/2022 Request For Change 17
03/10/2022 Outgoing Correspondence 3